206 related articles for article (PubMed ID: 28662827)
1. The Roles of Matrix Metalloproteinases in Pancreatic Cancer.
Knapinska AM; Estrada CA; Fields GB
Prog Mol Biol Transl Sci; 2017; 148():339-354. PubMed ID: 28662827
[TBL] [Abstract][Full Text] [Related]
2. Role of MT-MMPs and MMP-2 in pancreatic cancer progression.
Ellenrieder V; Alber B; Lacher U; Hendler SF; Menke A; Boeck W; Wagner M; Wilda M; Friess H; Büchler M; Adler G; Gress TM
Int J Cancer; 2000 Jan; 85(1):14-20. PubMed ID: 10585576
[TBL] [Abstract][Full Text] [Related]
3. Extracellular matrix-mediated membrane-type 1 matrix metalloproteinase expression in pancreatic ductal cells is regulated by transforming growth factor-beta1.
Ottaviano AJ; Sun L; Ananthanarayanan V; Munshi HG
Cancer Res; 2006 Jul; 66(14):7032-40. PubMed ID: 16849548
[TBL] [Abstract][Full Text] [Related]
4. Expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human pancreatic adenocarcinomas: clinicopathologic and prognostic significance of matrilysin expression.
Yamamoto H; Itoh F; Iku S; Adachi Y; Fukushima H; Sasaki S; Mukaiya M; Hirata K; Imai K
J Clin Oncol; 2001 Feb; 19(4):1118-27. PubMed ID: 11181677
[TBL] [Abstract][Full Text] [Related]
5. Matrix metalloproteinases and their role in pancreatic cancer: a review of preclinical studies and clinical trials.
Bloomston M; Zervos EE; Rosemurgy AS
Ann Surg Oncol; 2002 Aug; 9(7):668-74. PubMed ID: 12167581
[TBL] [Abstract][Full Text] [Related]
6. miR-221/222 induces pancreatic cancer progression through the regulation of matrix metalloproteinases.
Xu Q; Li P; Chen X; Zong L; Jiang Z; Nan L; Lei J; Duan W; Zhang D; Li X; Sha H; Wu Z; Ma Q; Wang Z
Oncotarget; 2015 Jun; 6(16):14153-64. PubMed ID: 25883224
[TBL] [Abstract][Full Text] [Related]
7. Pleiotropic Roles of Metalloproteinases in Hematological Malignancies: an Update.
Chaudhary AK; Chaudhary S; Ghosh K; Nadkarni A
Asian Pac J Cancer Prev; 2016; 17(7):3043-51. PubMed ID: 27509927
[TBL] [Abstract][Full Text] [Related]
8. Is there new hope for therapeutic matrix metalloproteinase inhibition?
Vandenbroucke RE; Libert C
Nat Rev Drug Discov; 2014 Dec; 13(12):904-27. PubMed ID: 25376097
[TBL] [Abstract][Full Text] [Related]
9. Expression of matrix metalloproteinases (MMP-2, MMP-9, MT1-MMP) and their inhibitors (TIMP-1, TIMP-2) in common epithelial tumors of the ovary.
Sakata K; Shigemasa K; Nagai N; Ohama K
Int J Oncol; 2000 Oct; 17(4):673-81. PubMed ID: 10995877
[TBL] [Abstract][Full Text] [Related]
10. Cellular contractility and extracellular matrix stiffness regulate matrix metalloproteinase activity in pancreatic cancer cells.
Haage A; Schneider IC
FASEB J; 2014 Aug; 28(8):3589-99. PubMed ID: 24784579
[TBL] [Abstract][Full Text] [Related]
11. [The role of metalloproteinases and their inhibitors in pancreatic cancer].
Łukaszewicz M; Mroczko B; Szmitkowski M
Postepy Hig Med Dosw (Online); 2008 Apr; 62():141-7. PubMed ID: 18414340
[TBL] [Abstract][Full Text] [Related]
12. Functional Roles of Matrix Metalloproteinases and Their Inhibitors in Melanoma.
Napoli S; Scuderi C; Gattuso G; Bella VD; Candido S; Basile MS; Libra M; Falzone L
Cells; 2020 May; 9(5):. PubMed ID: 32392801
[TBL] [Abstract][Full Text] [Related]
13. Matrix metalloproteinases (MMPs), the main extracellular matrix (ECM) enzymes in collagen degradation, as a target for anticancer drugs.
Jabłońska-Trypuć A; Matejczyk M; Rosochacki S
J Enzyme Inhib Med Chem; 2016; 31(sup1):177-183. PubMed ID: 27028474
[TBL] [Abstract][Full Text] [Related]
14. Matrix Metalloproteinases: A challenging paradigm of cancer management.
Alaseem A; Alhazzani K; Dondapati P; Alobid S; Bishayee A; Rathinavelu A
Semin Cancer Biol; 2019 Jun; 56():100-115. PubMed ID: 29155240
[TBL] [Abstract][Full Text] [Related]
15. Matrix metalloproteinase inhibition by heterotrimeric triple-helical Peptide transition state analogues.
Bhowmick M; Stawikowska R; Tokmina-Roszyk D; Fields GB
Chembiochem; 2015 May; 16(7):1084-92. PubMed ID: 25766890
[TBL] [Abstract][Full Text] [Related]
16. Seesaw of matrix metalloproteinases (MMPs).
Kapoor C; Vaidya S; Wadhwan V; ; Kaur G; Pathak A
J Cancer Res Ther; 2016; 12(1):28-35. PubMed ID: 27072206
[TBL] [Abstract][Full Text] [Related]
17. Potential clinical applications of matrix metalloproteinase inhibitors and their future prospects.
Li W; Saji S; Sato F; Noda M; Toi M
Int J Biol Markers; 2013 Jun; 28(2):117-30. PubMed ID: 23787494
[TBL] [Abstract][Full Text] [Related]
18. Matrix Metalloproteinases Inhibitors in Cancer Treatment: An Updated Review (2013-2023).
Almutairi S; Kalloush HM; Manoon NA; Bardaweel SK
Molecules; 2023 Jul; 28(14):. PubMed ID: 37513440
[TBL] [Abstract][Full Text] [Related]
19. ERK1/2 and p38 MAP kinase control MMP-2, MT1-MMP, and TIMP action and affect cell migration: a comparison between mesothelioma and mesothelial cells.
Zhong J; Gencay MM; Bubendorf L; Burgess JK; Parson H; Robinson BW; Tamm M; Black JL; Roth M
J Cell Physiol; 2006 May; 207(2):540-52. PubMed ID: 16447244
[TBL] [Abstract][Full Text] [Related]
20. Modulation of uPA, MMPs and their inhibitors by a novel nutrient mixture in human colorectal, pancreatic and hepatic carcinoma cell lines.
Roomi MW; Kalinovsky T; Niedzwiecki A; Rath M
Int J Oncol; 2015 Jul; 47(1):370-6. PubMed ID: 25997494
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
